Oral MS drug Cladribine 'Shuts Down MS Activity'
Oral MS drug Cladribine 'Shuts Down MS Activity'
Cladribine, an oral drug already marketed for hematologic cancers under the trade name Leustatin, was superior to placebo in reducing progression and other signs of MS disease activity, researchers reported at CMSC-ACTRIMS.
Freedom from any disease activity, including relapse, disability progression, or MRI progression, was experienced by 44.3% of patients treated with a high-dose of cladribine, and 43% of patients randomized to a low-dose regimen compared with 16% of placebo patients (P<0.001), said Gavin Giovannoni, PhD, from the Blizard Institute of Cell and Molecular Science at the Barts and the London School of Medicine and Dentistry in London, England.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
I just don't know whether to believe them or not:(
Its so terrible not to be able to trust your dr's and the scientists but years of bad experiences with the medical establishment as led me to question everything they say (and do).
I really do hope it works and that the side effects are not too severe like PML or death!
Its so terrible not to be able to trust your dr's and the scientists but years of bad experiences with the medical establishment as led me to question everything they say (and do).
I really do hope it works and that the side effects are not too severe like PML or death!
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 169 Views
-
Last post by NHE
-
- 0 Replies
- 1214 Views
-
Last post by frodo
-
- 0 Replies
- 1030 Views
-
Last post by frodo
-
- 1 Replies
- 1574 Views
-
Last post by ElliotB
-
- 0 Replies
- 1086 Views
-
Last post by NHE
-
- 1 Replies
- 1147 Views
-
Last post by Petr75
-
- 0 Replies
- 557 Views
-
Last post by NHE
-
- 0 Replies
- 1683 Views
-
Last post by NHE
-
- 1 Replies
- 3185 Views
-
Last post by Tif